|Minimum Order Quantity||2 Vial|
|Composition||Secukinumab Powder for solution for injection|
|Packaging Size||150 ml|
|Product Type|| Finished Product|
|Type of Medicines||Allopathic|
|Form Of Medicines||Injection|
Secukinumab, trade name Cosentyx, is a human IgG1 monoclonal antibody that binds to the protein interleukin (IL)-17A, and is marketed by Novartis for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It is used to treat psoriasis, ankylosing spondylitis, and psoriatic arthritis. It is given by subcutaneous injection and is sold in a pre-filled syringe or autoinjector that can be used at home and as a lyophilized powder for use in hospitals and clinics. Secukinumab was not tested in pregnant women animal studies did not show harm at relevant doses. The FDA advises that the drug should be used in pregnant women only if the risk to the fetus justifies the potential benefit, the EMA advises that women should not become pregnant while taking it.
- Pay Mode Terms: T/T (Bank Transfer)